Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes.

Clicks: 290
ID: 88060
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The mechanism of action of empagliflozin in heart failure with reduced ejection fraction (HFrEF) was deciphered using deep learning in silico analyses together with in vivo validation. The most robust mechanism of action involved the sodium-hydrogen exchanger (NHE)-1 co-transporter with 94.7% accuracy, which was similar for diabetics and nondiabetics. Notably, direct NHE1 blockade by empagliflozin ameliorated cardiomyocyte cell death by restoring expression of X-linked inhibitor of apoptosis (XIAP) and baculoviral IAP repeat-containing protein 5 (BIRC5). These results were independent of diabetes mellitus comorbidity, suggesting that empagliflozin may emerge as a new treatment in HFrEF.
Reference Key
iborraegea2019unravelingjacc Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Iborra-Egea, Oriol;Santiago-Vacas, Evelyn;Yurista, Salva R;Lupón, Josep;Packer, Milton;Heymans, Stephane;Zannad, Faiez;Butler, Javed;Pascual-Figal, Domingo;Lax, Antonio;Núñez, Julio;de Boer, Rudolf A;Bayés-Genís, Antoni;
Journal jacc basic to translational science
Year 2019
DOI
10.1016/j.jacbts.2019.07.010
URL
Keywords
Machine learning empagliflozin heart failure ann, artificial neural network dm, diabetes mellitus hf, heart failure hfref, hf with reduced ejection fraction mi-hf, post-infarct heart failure nhe, sodium-hydrogen exchanger rnaseq, rna sequencing sglt2i, sodium-glucose co-transporter 2 inhibitor

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.